Medicare rolls out significant changes in 2024 that reshape both drug costs and out-of-pocket expenses for beneficiaries. Understanding these shifts helps you plan healthcare spending more effectively.
Drug price negotiations hit hard this year. Medicare now directly negotiates prices with pharmaceutical manufacturers on ten high-cost drugs, including blood thinner Eliquis, diabetes drug Farxiga, and heart failure medication Entresto. The negotiated prices take effect January 2025 and will reduce what Medicare pays, translating to lower premiums and cost-sharing for enrollees using these medications.
However, other costs climb. The Part B deductible jumped to $240 in 2024, up from $226 the prior year. Part D (prescription drug) premiums vary widely by plan, but many beneficiaries face higher monthly charges. Standard Part B premiums remain at $175.50 for most enrollees, though higher-income beneficiaries pay more through income-related adjustments.
The Part D donut hole, technically called the coverage gap, shrinks further. In 2024, once you spend $4,700 in drug costs, you enter the gap where you pay 25 percent of brand-name drug costs (down from previous years). This gap closes at $7,050 in out-of-pocket spending, after which catastrophic coverage kicks in.
New rules expand telehealth options. Medicare now covers more virtual visits with specialists, reducing travel burdens for rural and mobility-limited beneficiaries. Prior authorization requirements changed for certain treatments, potentially speeding access to needed care.
For those choosing standalone plans, attention matters. Medicare Advantage plans (Part C) often carry lower premiums than Original Medicare plus separate Medigap coverage, but they typically impose network restrictions and require prior authorizations. Beneficiaries switching plans must enroll during the October